Sun Pharma announces settlement of patent litigation for Generic Revlimid® (lenalidomide) in US

Sun Pharma announces settlement of patent litigation for Generic Revlimid® (lenalidomide) in US ​​Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022. https://ift.tt/eA8V8J